Thymic malignancies: From clinical management to targeted therapies Review uri icon

Overview

MeSH Major

  • Thymus Neoplasms

abstract

  • Drug development for the treatment of thymic malignancies is difficult because of the rarity of these tumors. Ethnic differences are becoming apparent, with aggressive subtypes being observed in Asians and African Americans. Incremental improvements in our understanding of tumor biology suggest that molecular profiling-directed therapies may be the preferred route of investigation in the future.

publication date

  • December 20, 2011

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3675690

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.36.0487

PubMed ID

  • 22105817

Additional Document Info

start page

  • 4820

end page

  • 7

volume

  • 29

number

  • 36